Mechanical circulatory support devices as destination therapy-current evidence.

Area of Science:

• Cardiology
• Medical Devices
• Heart Failure Management

Background:

• Advanced heart failure is a growing global health concern.
• Mechanical circulatory support devices (MCSD) are an established treatment for end-stage heart failure.
• Destination therapy (DT) is increasingly utilized due to donor organ scarcity and patient eligibility for heart transplantation.

Purpose of the Study:

• To review current evidence for left ventricular assist device (LVAD) implantation for destination therapy in advanced heart failure.
• To emphasize key considerations including patient selection, optimal implantation timing, device choice, and long-term outcomes.
• To address ongoing challenges such as device biocompatibility and optimal implantation timing.

Main Methods:

• Review of current literature and evidence regarding LVADs for destination therapy.
• Analysis of patient selection criteria and implantation strategies.
• Evaluation of long-term outcomes, quality of life, and device-related complications.

Main Results:

• LVADs have improved survival and quality of life for patients with advanced heart failure.
• Continuous flow left ventricular devices offer enhanced durability and smaller profiles.
• Common complications include bleeding, infection, thrombosis, and cerebrovascular events.

Conclusions:

• Destination therapy with LVADs is a crucial option for patients with end-stage heart failure.
• Further research is needed to optimize implantation timing and improve device biocompatibility.
• LVADs significantly enhance long-term outcomes and quality of life for eligible patients.